Yutian Zou
Novel Implication of the Basement Membrane for Breast Cancer Outcome and Immune Infiltration. Advances in artificial intelligence to predict cancer immunotherapy efficacy. Integrative …
The Single-Cell Landscape of Intratumoral Heterogeneity and The ...
In summary, this study dissects the intratumoral heterogeneity and immunosuppressive microenvironment in liver and brain metastases of breast cancer for the first time, providing …
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell
2022年5月13日 · Intrinsic and acquired anti-HER2 resistance remains a major hurdle for treating HER2-positive breast cancer. Using genome-wide CRISPR/Cas9 screening in vitro and in …
Yutian Zou - Google Scholar
University of California, Berkeley - Cited by 319 - Molecular Therapeutics
The PROTAC technology in drug development - PubMed
Currently, a new technology termed PROTAC, proteolysis targeting chimera, has been developed for inducing the protein degradation by a targeting molecule. This technology takes advantage …
Yutian Zou | Sun Yat-sen University | 24 Publications | 36 Citations ...
Yutian Zou is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 13, co-authored 24 …
The PROTAC technology in drug development - Zou - 2019 - Cell ...
2019年1月2日 · Currently, a new technology termed PROTAC, proteolysis targeting chimera, has been developed for inducing the protein degradation by a targeting molecule. This technology …
A cell-permeable peptide-based PROTAC against the oncoprotein …
To provide a proof of concept for CREPT as a new target for the inhibition of pancreatic cancer, we designed a cell-permeable peptide-based proteolysis targeting chimera (PROTAC), named …
Yutian Zou - Loop
2024年12月17日 · This researcher does not have an active role on a Frontiers editorial board. You may recommend their participation here.
Yutian Zou - SciProfiles
Fifth Affiliated Hospital of... Multidisciplinary Digital Pu...